Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012)
Bausch Health Companies (BHC) posted Non-Current Deffered Revenue of $36.1 million for Q4 2012, down 1.63% sequentially from $36.7 million in Q3 2012, and down 5.31% YoY from $38.2 million in Q1 2012.
Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012) Analysis & Trends
Bausch Health Companies has reported Non-Current Deffered Revenue for 4 years, with the latest figure at $36.1 million in Q4 2012.
- Quarterly Non-Current Deffered Revenue fell 5.31% year-over-year to $36.1 million in Q4 2012, while the trailing twelve-month figure through Dec 2012 was $36.1 million (down 5.31% YoY) and the FY2012 annual result came in at $36.1 million, down 5.31% from the prior year.
- Non-Current Deffered Revenue fell to $36.1 million in Q4 2012 per BHC's latest filing, from $36.7 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $69.2 million in Q4 2009 and troughed at $34.0 million in Q1 2012.
- A 4-year average of $45.5 million and a median of $42.0 million in 2011 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2011 and 2012: Non-Current Deffered Revenue retreated 28.5% in 2011, then declined 5.31% in 2012.
- Over 4 years, Non-Current Deffered Revenue stood at $69.2 million in 2009, then retreated by 27.76% to $50.0 million in 2010, then fell by 23.73% to $38.2 million in 2011, then fell by 5.31% to $36.1 million in 2012.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $36.1 million, $36.7 million, and $37.9 million for Q4 2012, Q3 2012, and Q2 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 36.13 Mn |
| Sep 30, 2012 | 36.73 Mn |
| Jun 30, 2012 | 37.90 Mn |
| Mar 31, 2012 | 33.97 Mn |
| Dec 31, 2011 | 38.15 Mn |
| Sep 30, 2011 | 41.41 Mn |
| Jun 30, 2011 | 42.51 Mn |
| Mar 31, 2011 | 45.02 Mn |
| Dec 31, 2010 | 50.02 Mn |
| Sep 30, 2010 | 55.03 Mn |
| Jun 30, 2010 | 59.45 Mn |
| Dec 31, 2009 | 69.25 Mn |